Success Metrics

Clinical Success Rate
81.3%

Based on 330 completed trials

Completion Rate
81%(330/406)
Active Trials
85(14%)
Results Posted
62%(206 trials)
Terminated
76(13%)

Phase Distribution

Ph phase_3
74
13%
Ph phase_2
287
48%
Ph early_phase_1
6
1%
Ph phase_1
186
31%
Ph not_applicable
28
5%
Ph phase_4
3
1%

Phase Distribution

192

Early Stage

287

Mid Stage

77

Late Stage

Phase Distribution584 total trials
Early Phase 1First-in-human
6(1.0%)
Phase 1Safety & dosage
186(31.8%)
Phase 2Efficacy & side effects
287(49.1%)
Phase 3Large-scale testing
74(12.7%)
Phase 4Post-market surveillance
3(0.5%)
N/ANon-phased studies
28(4.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.5%

330 of 437 finished

Non-Completion Rate

24.5%

107 ended early

Currently Active

85

trials recruiting

Total Trials

592

all time

Status Distribution
Active(96)
Completed(330)
Terminated(107)
Other(59)

Detailed Status

Completed330
Terminated76
unknown56
Recruiting45
Active, not recruiting40
Withdrawn31

Development Timeline

Analytics

Development Status

Total Trials
592
Active
85
Success Rate
81.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (1.0%)
Phase 1186 (31.8%)
Phase 2287 (49.1%)
Phase 374 (12.7%)
Phase 43 (0.5%)
N/A28 (4.8%)

Trials by Status

unknown569%
completed33056%
not_yet_recruiting112%
terminated7613%
active_not_recruiting407%
recruiting458%
suspended31%
withdrawn315%

Recent Activity

Clinical Trials (592)

Showing 20 of 592 trialsScroll for more
NCT02443077Phase 3

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Active Not Recruiting
NCT05564390Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Recruiting
NCT06287944Phase 1

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Recruiting
NCT00114101Phase 3

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Active Not Recruiting
NCT06172296Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Recruiting
NCT06207799Phase 2

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Recruiting
NCT02727803Phase 2

Personalized NK Cell Therapy in CBT

Recruiting
NCT03259503Phase 1

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Completed
NCT05457556Phase 3

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Active Not Recruiting
NCT07281924Phase 1

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Recruiting
NCT03849651Phase 2

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active Not Recruiting
NCT04370301Phase 2

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Recruiting
NCT07257419Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Recruiting
NCT04022239Phase 1

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Recruiting
NCT06377540Phase 2

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Recruiting
NCT07605416Phase 2

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Not Yet Recruiting
NCT05139004Phase 1

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Active Not Recruiting
NCT00602641Phase 3

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Active Not Recruiting
NCT06996119Phase 1

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Recruiting
NCT03494569Phase 1

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Suspended

Drug Details

Intervention Type
DRUG
Total Trials
592